Lepu Biopharma Co., Ltd. (2157.HK) HKSE
4.02
-0.12(-2.90%)
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.02
-0.12(-2.90%)
Currency In HKD
Sector
Healthcare
Industry
Biotechnology
Employees
498
First IPO Date
February 23, 2022
| Name | Title | Pay | Year Born |
| Ziye Sui | GM, CEO & Executive Director | 4.02M | 1981 |
| Yunyi Li | CFO & Joint Company Secretary | 0 | 1981 |
| Lixuan Zhao | Employee Representative Supervisor & Investor Relations Director | 0 | 1993 |
| Siu Kuen Lai FCIS | Joint Company Secretary | 0 | 1976 |
| Zhongjie Pu | Executive Chairman | 0 | 1963 |
Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on developing oncology therapeutics with a pipeline designed with a range of oncology products in China. The company develops oncology drug candidates, including antibody-drug conjugates (ADC), oncolytic virus drugs, and immunotherapies. It develops immuno-oncology products, such as HX008 Anti-PD-1 mAb and LP002 Anti-PD-L1 mAb; ADC products, including MRG003 EGFR-targeted ADC, MRG002 HER2-targeted ADC, MRG001 CD20-targeted ADC, MRG004A TF-targeted ADC, and CMG901 CLDNI8.2-targeted ADC; CG0070 oncolytic virus; and other drug candidates, such as HX008+OH2, LP002+OH2, and HX008+LP002. The company was incorporated in 2018 and is headquartered in Shanghai, China.